Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer

医学 新辅助治疗 胰腺癌 胰腺切除术 吉西他滨 叶黄素 外科 癌症 肿瘤科 入射(几何) 化疗 内科学 胰腺 伊立替康 乳腺癌 结直肠癌 物理 光学
作者
Samuel Cass,Ching‐Wei D. Tzeng,Laura R. Prakash,Jessica Maxwell,Rebecca A. Snyder,Michael P. Kim,Ryan Huey,Brandon G. Smaglo,Shubham Pant,Eugene J. Koay,Robert A. Wolff,Jeffery E. Lee,Matthew H. G. Katz,Naruhiko Ikoma
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:282 (6): 1024-1033 被引量:9
标识
DOI:10.1097/sla.0000000000006269
摘要

Objective: We aimed to determine if advances in neoadjuvant therapy affected recurrence patterns and survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). Background: Data are limited on how modern multimodality therapy affects PDAC recurrence and postrecurrence survival. Methods: Patients who received neoadjuvant therapy followed by curative-intent pancreatectomy for PDAC during 1998-2018 were identified. Treatments, recurrence sites and timing, and survival were compared between patients who completed neoadjuvant therapy and pancreatectomy during 1998-2004, 2005-2011, and 2012-2018. Results: The study included 727 patients (203, 251, and 273 in the 1998-2004, 2005-2011, and 2012-2018 cohorts, respectively). The use of neoadjuvant induction chemotherapy increased over time, and regimens changed over time, with >80% of patients treated in 2012-2018 receiving FOLFIRINOX or gemcitabine with nab-paclitaxel. Overall, recurrence sites and incidence (67.5%, 66.1%, and 65.9%) remained stable, and 85% of recurrences occurred within 2 years of surgery. However, compared with earlier cohorts, the 2012-2018 cohort had a lower conditional risk of recurrence in postoperative year 1 and a higher risk in postoperative year 2. Overall survival increased over time (median, 30.6, 33.6, and 48.7 mo, P < 0.005), driven by improved postrecurrence overall survival (median, 7.8, 12.5, and 12.6 mo; 3-year rate, 7%, 10%, and 20%; P < 0.005). Conclusions: We observed changes in neoadjuvant therapy regimens over time and an associated shift in the conditional risk of recurrence from postoperative year 1 to postoperative year 2, although recurrence remained common. Overall survival and postrecurrence survival remarkably improved over time, reflecting improved multimodality regimens for recurrent disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhengyf发布了新的文献求助10
刚刚
飞1发布了新的文献求助10
刚刚
刚刚
豆浆完成签到,获得积分0
1秒前
LMH发布了新的文献求助10
1秒前
ccq的应助被DiJia采纳,获得10
1秒前
顾矜的应助被ddd采纳,获得10
1秒前
SZW发布了新的文献求助10
2秒前
jiejie完成签到,获得积分20
2秒前
thisXiao6发布了新的文献求助10
2秒前
盛志孟发布了新的文献求助10
2秒前
SWZ发布了新的文献求助10
3秒前
3秒前
darkmonmon完成签到,获得积分10
3秒前
万能图书馆的应助被六六采纳,获得10
3秒前
advance完成签到,获得积分10
3秒前
欧阳香彤完成签到,获得积分10
3秒前
沉默毛衣发布了新的文献求助10
3秒前
4秒前
xiaomo完成签到,获得积分10
4秒前
hah发布了新的文献求助10
4秒前
4秒前
4秒前
安靖发布了新的文献求助10
4秒前
4秒前
是个熊猫发布了新的文献求助10
5秒前
今天学习了嘛完成签到,获得积分10
5秒前
5秒前
落寞冬萱发布了新的文献求助10
5秒前
5秒前
莺时完成签到 ,获得积分10
5秒前
www完成签到,获得积分10
5秒前
LCCL完成签到,获得积分20
6秒前
美好黑猫完成签到,获得积分10
6秒前
鹤轸发布了新的文献求助10
6秒前
李爱国的应助被小小小珂卿采纳,获得10
7秒前
桐桐的应助被DiJia采纳,获得10
7秒前
7秒前
hah完成签到,获得积分10
7秒前
是小鱼完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8169459
求助须知:如何正确求助?哪些是违规求助? 9562535
关于积分的说明 21766045
捐赠科研通 7761050
什么是DOI,文献DOI怎么找? 3430397
关于科研通互助平台的介绍 2554220
邀请新用户注册赠送积分活动 2475026